Although sunitinib is used clinically to treat c-KIT driven GISTs, efficient growth inhibition of HT-29 CRC cells or xenografts requires a simultaneous block of EGFR [18, 19] or c-MET [20] kinases, in addition to BRAFV600E, consistent with the very low response rate (about 5 %) in BRAF-mutant CRCs. Here, KIT is linked to colorectal carcinoma.